YSYejun Son

Yejun Son

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yejun Son has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular adverse events of tocilizumab and baricitinib in COVID-19 and rheumatoid arthritis

    by Junmo Moon, Chaemin Lee, Seoyeong Lee, Meehoh Kim, Xuerong Wen, Francesco Branda, Jeongseon Oh, Yejun Son, Kyeongmin Lee, Taelim Choi, et al.

    Tocilizumab and baricitinib are used in rheumatoid arthritis (RA) and COVID-19, where acute hyperinflammation and systemic stress may amplify cardiovascular risk. Comparative evidence on indication-specific cardiovascular signals remains scarce; we therefore assessed these signals by indication. We analyzed the FDA Adverse Event Reporting System data from January 2010 to June 2025 to compare cardiovascular adverse events (CVAEs) associated with baricitinib and tocilizumab. Primary outcomes included 6 CVAE categories: cardiac arrhythmias, central nervous system vascular disorders, embolic and thrombotic events, ischemic heart disease, noninfectious myocarditis/pericarditis, and other cardiac disorders. Disproportionality was assessed using the information component (IC) and reporting odds ratio (ROR), stratified by pre- and post-COVID-19 Emergency Use Authorization (EUA) periods and indications (COVID-19 vs RA). Machine learning models were additionally trained to characterize risk patterns for each drug, with feature contributions interpreted using SHapley Additive exPlanations. Among 17,750,053 reports, 5994 CVAEs were identified (baricitinib, n = 965; tocilizumab, n = 5029). Disproportionality was higher in the post-EUA than the pre-EUA period for both baricitinib (IC, 0.84 [IC 025 , 0.59] to 1.51 [1.39]; ROR, 1.89 [95% confidence interval, 1.62–2.21] to 3.22 [2.98–3.48]) and tocilizumab (0.22 [0.16] to 0.54 [0.47]; 1.18 [1.14–1.23] to 1.50 [1.43–1.57]). Baricitinib for COVID-19 showed the highest disproportionality (IC, 2.90 [IC 025 , 2.70]; ROR, 11.95 [95% confidence interval, 10.33–13.83]). Gradient boosting machine achieved the highest AUROC (baricitinib, 0.728; tocilizumab, 0.702), and SHapley Additive exPlanations highlighted COVID-19 indication for baricitinib and RA for tocilizumab. Our findings suggest indication-dependent cardiovascular signals when immunomodulators are repurposed for acute viral infections, underscoring the need for context-aware evaluation in drug repurposing.

  • Open Access

    National trends in chronic kidney disease prevalence by sleep duration in South Korea, 2007 to 2022

    by Jeongseon Oh, Yesol Yim, Hyeon Jin Kim, Sunyoung Kim, Yejun Son, Seoyoung Park, Jaeyu Park, Hyunjee Kim, Lee Smith, Guillermo F. López Sánchez, et al.

    Despite growing evidence linking sleep duration to chronic kidney disease (CKD), long-term trend analyses specific to the Korean population remain limited, and most previous studies have relied on broad intermediate sleep categories. This study analyzed trends in CKD prevalence by self-reported sleep duration among Korean adults. We included 87,246 Korean adults aged ≥19 years from the Korea National Health and Nutrition Examination Survey, 2007 to 2022. CKD was defined as an estimated glomerular filtration rate 2 . Sleep duration was categorized into 5 groups (<6, 6–7, 7–8, 8–9, and ≥9 hours), with 7 to 8 hours as the reference. Weighted linear and logistic regression models provided β-coefficients and weighted odds ratios with 95% confidence intervals, sequentially adjusted for age, sex, body mass index, region, household income, education, smoking status, physician-diagnosed diabetes mellitus, hypertension, and dyslipidemia, and perceived stress. CKD prevalence declined across all 5 categories from 2007 to 2009 to 2020 to 2022 (<6 hours, 5.13% [95% confidence intervals, 4.12–6.13]–3.53% [2.74–4.33]; 7 to 8 hours, 2.37% [1.82–2.93]–1.52% [1.16–1.89]; ≥9 hours, 4.33% [3.17–5.48]–2.95% [2.18–3.72]). A U-shaped association was observed: relative to 7 to 8 hours, the fully adjusted odds of CKD were higher for .05). In conclusion, CKD prevalence showed a U-shaped association with sleep duration that persisted after adjustment for cardiometabolic comorbidity and perceived stress. The absence of a significant change across the pandemic threshold should be interpreted in light of the short observation window relative to the natural history of CKD.

  • Open Access

    Comparative effectiveness of pioglitazone and sitagliptin added to metformin and sulfonylurea in patients with type 2 diabetes

    by Tae Hyeon Kim, Yerin Hwang, Selin Woo, Kyeongmin Lee, Yejun Son, Seoyoung Park, Hyunjee Kim, Ju-Young Shin, YongHyun Cho, Dahye Shin, et al.

    Dipeptidyl peptidase-4 inhibitors and thiazolidinediones are commonly used as add-ons in type 2 diabetes mellitus (T2DM) treatment, but comparative data are limited. This study emulated a target trial to compare sitagliptin and pioglitazone in patients on metformin and sulfonylurea, focusing on changes in glycemic control and clinical outcomes. This emulated target trial comprised 68,372 patients with T2DM identified from 4 university hospitals in South Korea (2001–2024). Patients with T2DM receiving both metformin and sulfonylurea were included and assigned to groups receiving either pioglitazone or sitagliptin as add-on therapy using 1:1 propensity score matching. Clinical indicators, including glycemic parameters, were evaluated for differences between groups using unpaired t-tests during the 24-week follow-up. To assess the possibility of achieving intensive glycemic control (HbA1c < 6.5%), Cox proportional hazards analysis was performed, reporting adjusted hazard ratio (aHR) with 95% confidence intervals (CIs). Following 1:1 propensity score matching, 1742 participants were assigned to each of the pioglitazone (mean age, 58.75 years; 64.7% male) and sitagliptin (mean age, 58.95 years; 64.7% male) groups. Both pioglitazone and sitagliptin reduced HbA1c over 24 weeks with no significant between-group difference (pioglitazone: −0.48% [95% CI, −0.55 to −0.41]; sitagliptin: −0.55% [95% CI, −0.61 to −0.48]; P -value = .182 for the between-group difference). However, sitagliptin was associated with a higher possibility of achieving HbA1c < 6.5% (aHR, 1.28 [95% CI, 1.08–1.53]), and showed greater reductions in body weight (pioglitazone: 0.26 kg [95% CI, −0.37 to 0.89]; sitagliptin: −0.91 kg [95% CI, −1.65 to −0.17]; P -value = .018 for the between-group difference) and LDL cholesterol (pioglitazone: −2.22 mmol/L [95% CI, −7.41 to 2.96]; sitagliptin: −11.42 mmol/L [95% CI, −16.95 to −5.89]; P -value = .017 for the between-group difference). Our findings suggest that sitagliptin showed more favorable metabolic profiles and a higher likelihood of achieving intensive glycemic targets compared with pioglitazone, beyond average glycemic control.

  • Top Cited Papers
    Open Access

    Gestational Diabetes Mellitus and Adverse Maternal and Neonatal Health Outcomes: an Umbrella review of Meta‐Analyses

    by Jiseung Kang, Hyeon Jin Kim, Yeona Jo, Kathryn J. Smith, Arianna R. S. Lark, Fayaz A. Mir, Jaeyu Park, Hayeon Lee, Yumin Kim, Masoud Rahmati, et al.

    Introduction: This study systematically synthesized evidence on adverse health outcomes related to gestational diabetes mellitus (GDM) via an umbrella review with integrated meta‐analyses. Methods: The search covered publications from the database (PubMed/MEDLINE, Google Scholar, Embase, and CINAHL) inception to August 12, 2024. Meta‐analyses of observational studies examining the impact of GDM on maternal and neonatal health outcomes were included. Two independent researchers screened and extracted data. Associations were reanalyzed and presented as equivalent odds ratios (eORs) with 95% confidence intervals (CI). The quality of meta‐analyses was assessed using AMSTAR 2, and the credibility of associations was categorized into five levels: convincing (Class I), highly suggestive (Class II), suggestive (Class III), weak (Class IV), or nonsignificant (NS). Results: A total of 27 meta‐analyses encompassing 85 associations were included. Among 28 significant maternal outcomes, 11 (subclinical atherosclerosis, angina, hypertension, overall cardiovascular diseases, ischemic stroke, overall stroke, combined cardiovascular/cerebrovascular diseases, subclinical left ventricle systolic dysfunction, type 2 diabetes, postpartum metabolic syndrome, and infections) were supported by convincing or highly suggestive evidence. Of 13 significant neonatal outcomes, three (atrial septal defect, congenital heart disease, and ventricular septal defect) were highly suggestive, while four of eight significant delivery outcomes (hypertensive disorders, cesarean delivery, admission to neonatal intensive care unit admission, and preterm birth) reached this level. Notably, no outcomes previously deemed nonsignificant turned significant upon reanalysis. Conclusions: These findings underscore the need for targeted prevention and management, and further research is needed to clarify causality and refine guidelines. Study registration: PROSPERO CRD42024590322


  • Open Access

    Long-term effectiveness on glycemic control of insulin compared to combined oral antidiabetic drugs for initial intensive treatment in newly diagnosed type 2 diabetes: A duplicated target trial

    by Tae Hyeon Kim, Yerin Hwang, Selin Woo, Kyeongmin Lee, Yejun Son, Seoyoung Park, Hyunjee Kim, Ju-Young Shin, YongHyun Cho, Dahye Shin, et al.

    Although both intensive insulin therapy (IIT) and combined oral antidiabetic drugs (COAD) can achieve initial intensive glycemic control, evidence comparing their long-term effectiveness following initial remission remains limited. Therefore, this study aims to compare long-term glycemic control and the risk of drug-free remission failure between IIT and COAD in patients who successfully achieved initial intensive glycemic control. This duplicated target trial utilized a cohort of 60,736 patients with type 2 diabetes from 3 hospitals in South Korea (2001–2024). Patients treated with insulin were assigned to the IIT group, and those receiving metformin combined with other oral antidiabetic drugs to the COAD group. Successful initial intensive treatment was defined as HbA1c <7.0% following treatment cessation. Failure of drug-free glycemic remission was defined as HbA1c ≥7.0% during follow-up. After 1:1 propensity score matching, Cox proportional hazard model was employed to evaluate the risk of remission failure between groups, estimating adjusted hazard ratios (aHRs) with 95% confidence intervals. Among 2092 patients achieving successful initial intensive treatment, each group assigned 355 following 1:1 propensity score matching (IIT group: mean age, 64.56 [standard deviation, 13.16] years; 49.0% female; COAD group: mean age, 64.08 [standard deviation, 12.90] years; 45.6% female). Baseline mean HbA1c and fasting plasma glucose were 6.26% and 115.4mg/dL in the IIT group, and 6.31% and 126.4mg/dL in the COAD group. During follow-up, HbA1c and body weight diverged significantly, with higher levels observed in the COAD group. The IIT group indicated a significant lower risk of drug-free glycemic remission failure compared to the COAD group (aHR, 0.47 [95% confidence interval, 0.31–0.73]). In patients with newly diagnosed type 2 diabetes achieving successful initial intensive treatment, IIT was associated with better long-term glycemic control compared with COAD, despite treatment discontinuation.

  • Open Access

    Association of Everyday Discrimination With Drug Use During the COVID-19 Pandemic in the All of Us Research Program

    by Jiseung Kang, Hyeon Jin Kim, Arianna R. S. Lark, Fayaz A. Mir, Jaeyu Park, Yejun Son, Guillaume Fond, Laurent Boyer, Masoud Rahmati, Lee Smith, et al.

    Objective Recognizing discrimination as a significant public health risk during the coronavirus disease 2019 (COVID-19) pandemic, which coincided with increased drug use and heightened awareness of structural disparities in the United States, we investigated its association with the odds of drug use in a large and diverse cohort from the All of Us Research Program.Methods In this cross-sectional study, data from 68,976 participants completed the COVID-19 participant experiences (COPE) survey. We applied logistic regression models with propensity score-based overlap weighting to examine associations between everyday discrimination and drug use. Self-reported everyday discrimination score and drug use were the primary exposure and outcome measures, respectively.Results Of the 67,662 COPE respondents (mean [standard deviation] age, 57.5 [15.9] years; female sex at birth, 43,658 [64.5%]), we identified 15,493 participants with no reported discrimination and 15,493 participants with reported discrimination, after overlap weighting. The odds of drug use in those who reported discrimination was 1.38 (95% confidence interval, 1.32–1.43), with a dose-dependent association based on discrimination score. Participants who experienced discrimination had significantly higher odds of using drugs and this association was particularly pronounced in those under 40 years of age, those assigned female sex at birth, current smokers, individuals undergoing chemotherapy or immunotherapy, and those experiencing unemployment or COVID-19/flu-like symptoms.Conclusion This relationship was observed across various types of drugs and different reasons for discrimination, and it was particularly pronounced in specific subgroups. These findings provide critical evidence for developing targeted preventive interventions; however, further longitudinal studies for causality are warranted.

  • Open Access

    National trends of unmet healthcare needs and risk factors by household income level, 2010 to 2022: A Nationwide cross-sectional study in South Korea

    by Hyunjee Kim, Jaeyu Park, Jinyoung Jeong, Saiah Kim, Hayeon Lee, Hyeon Jin Kim, Yejun Son, Soeun Kim, Sooji Lee, Kyeongmin Lee, et al.

    Socio-economic status plays a critical role in shaping unmet healthcare needs, and the COVID-19 pandemic has further intensified these disparities; however, research to date remains insufficient. Therefore, this study aims to analyze unmet healthcare needs by household income using large-scale longitudinal data (2010–2022) including pre- and post- pandemic differences. This large-scale study (n = 2,628,584) utilized nationwide data from the Korea Community Health Survey (KCHS) conducted between 2010 and 2022, administered by the Korea Disease Control and Prevention Agency. The analysis employed complex, weighted sampling to examine trends in unmet healthcare needs, with a specific focus on changes during the COVID-19 pandemic. Weighted logistic regression models were used to calculate odds ratios and β differences (β diff ) between the pre-pandemic (2010–2019) and pandemic (2020–2022) periods. In total, 2,628,584 individuals participated in the KCHS from 2010 to 2022, comprising 1,454,129 males (55.3%) and 1,174,455 females (44.7%). Before the pandemic, there was a consistent decline in the prevalence of unmet healthcare needs. However, following the onset of the pandemic, unmet healthcare needs increased (β diff, low-level of household income: 1.66 [95% CI, 1.41–1.92]; mid-level of household income: 0.88 [95% CI, 0.77–0.99]; high-level of household income: 0.71 [95% CI, 0.57–0.85]). Overall, households with lower incomes exhibited higher levels of unmet healthcare needs compared to those with higher incomes (low household income: 14.8 [95% CI, 13.91–14.24]; high household income: 8.45 [95% CI, 8.34–8.55]). Additionally, the disparity in healthcare access due to income differences was more pronounced among older individuals, those with lower educational attainment, and those with lower subjective health status. Our analysis found that older adults in low-income households consistently faced higher rates of unmet healthcare needs. The reversal of a pre-pandemic trend toward reducing healthcare gaps highlights the urgent need for targeted interventions to address socio-economic disparities.


  • Open Access

    Low- and no-calorie sweeteners and beverages and their associated health outcomes: an umbrella review of systematic reviews and meta-analyses

    by Jinyoung Jeong, Jaehyeong Cho, Yeona Jo, Dongjin Yeo, Jiyoung Hwang, Yejun Son, Seohyun Hong, Selin Woo, Masoud Rahmati, Lee Smith, et al.

    Jeong J, et al. Nutr Res Pract. 2026 Jun;20(3):382-397. https://doi.org/10.4162/nrp.2026.20.3.382

  • Open Access

    Post-Acute Sequelae of COVID-19 Across 15 Major Health Domains and 67 Diseases in Individuals With Depressive Disorder: A Korean Nationwide Cohort Study

    by Jaehyeong Cho, Selin Woo, Jaeyu Park, Yejun Son, Hyesu Jo, Hayeon Lee, Ho Geol Woo, Hanseul Cho, Guillaume Fond, Laurent Boyer, et al.

    Cho J, et al. J Korean Med Sci. 2026 Jul;41:e181. https://doi.org/10.3346/jkms.2026.41.e181